My SciELO
Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Cited by Google
- Similars in SciELO
- Similars in Google
Share
Farmacia Hospitalaria
On-line version ISSN 2171-8695Print version ISSN 1130-6343
Abstract
BRANDARIZ-NUNEZ, David; HERNANDEZ-CORREDOIRA, Virginia; GUARC-PRADES, Eva and GARCIA-NAVARRO, Bárbara. Optic neuropathy associated with linezolid: systematic review of cases. Farm Hosp. [online]. 2019, vol.43, n.2, pp.61-65. ISSN 2171-8695. https://dx.doi.org/10.7399/fh.11133.
Objective:
Collect and analyze all the described cases of optic neuropathy associated with linezolid.
Method:
A systematic review of cases was carried out through a search in PubMed-Medline, Embase and ScienceDirect, between September 2002 and April 2018. The demographic, clinical and ophthalmology characteristics of each patient were evaluated.
Results:
A total of 33 cases from 26 independent articles were analyzed. The mean age was 44.97 ± 21.40 years (range: 6-79) and 16 (50%) of 32 cases were women. The duration of treatment with linezolid until onset of symptoms was greater than 28 days in 29 (90.6%) of 32 documented cases. The mean time of exposure to onset of symptoms was 8.5 ± 8.6 months (range: 0.33-50). A total of 12 of 26 adult patients received linezolid 600 mg/24 h, starting. In 30 (90.9%) patients loss of visual acuity was documented. Linezolid was withdrawn in all cases once the diagnosis was confirmed, with clinical improvement in 31 (93.9%) cases.
Conclusions:
Optic neuropathy is a reversible complication related to the prolonged use of linezolid and regardless of the dose. We recommend follow-up in patients with long treatments (> 28 days) and ophthalmological exploration in those with visual alterations for the early diagnosis of neuropathy and early withdrawal of linezolid.
Keywords : Linezolid; Multidrug resistant tuberculosis; Optic neuropathy; Oxazolidinones; Side effects.